Drug intelligence / Profile preview

OAK-019

Development stage: Preclinical
Lead developer: Oakrum Pharma
Modality: Small Molecules
Administration: Injectable

Overview

OAK-019 is a small molecule injectable drug candidate currently in the development stage at Oakrum Pharma. Oakrum Pharma is a specialty pharmaceutical company that focuses on the development and commercialization of generic and proprietary drug products. As of early 2024, the specific therapeutic indication, molecular target, and mechanism of action for OAK-019 have not been publicly disclosed by the developer. The candidate is listed in the company's pipeline as being in the early development phase, following the company's focus on high-value specialty and generic injectable medications.

Beyond the preview

Go deeper on OAK-019.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OAK-019.

Explore the full profile